Dr. Peter Mitchell, PhD
Peter Mitchell comes to IAG with 25 years of commercial pharmaceutical leadership focused on arthritis and inflammation, and has authored more than 50 peer-reviewed publications. He started his career in basic research in cartilage biology, leading drug discovery projects focused on arthritis and inflammation at Pfizer in Groton, Connecticut. In 2003, he joined Eli Lilly in Indianapolis, where he became Senior Director in the Translational Sciences, and then Tailored Therapeutics, Departments, with work focused on how to provide tailored therapeutics in the areas of autoimmune and musculoskeletal diseases. He earned a Ph.D. in analytical chemistry from New Mexico State University in Las Cruces, New Mexico. Following his graduate work, Dr. Mitchell completed post-doctoral research in cancer cell biology at Vanderbilt University in Nashville, Tennessee and then went on to perform rheumatology research for three years at the Medical College of Wisconsin in Milwaukee, Wisconsin.